Adma Biologics Inc EBITDA margin
What is the EBITDA margin of Adma Biologics Inc?
The EBITDA margin of Adma Biologics Inc is -94.70%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to Adma Biologics Inc
What does Adma Biologics Inc do?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Companies with ebitda margin similar to Adma Biologics Inc
- EYEMAXX Real Estate AG has EBITDA margin of -95.52%
- Alco has EBITDA margin of -95.32%
- MediPharm Labs has EBITDA margin of -95.17%
- Pharmaxis Ltd has EBITDA margin of -95.17%
- Lifespot Health Ltd has EBITDA margin of -95.05%
- King George has EBITDA margin of -94.99%
- Adma Biologics Inc has EBITDA margin of -94.70%
- Redhill Biopharma has EBITDA margin of -94.69%
- Turnium Technology Inc has EBITDA margin of -94.53%
- Clubhouse Media has EBITDA margin of -94.45%
- CAA Resources has EBITDA margin of -94.45%
- China Netcom Technology has EBITDA margin of -94.29%
- Blueprint Medicines Corp has EBITDA margin of -94.10%